Arbor Vita Commitment

Arbor Vita Corporation is a private company focused on defining the future of protein-based molecular diagnostics. The Company develops accurate diagnostics tests that detect infection or cancer related protein markers.

  • AVC OncoE6™ Products for Cervical Cancer Diagnostic

    Cancer Diagnostic

    Cancer remains a major cause of death in the developing- and the developed world. In India, for example, in average every 7 minutes a women dies from cervical cancer, a cancer that can be successfully treated if diagnosed early. Arbor Vita engages in the development of highly specific and simple to perform cancer diagnostic tests. The OncoE6™ Cervical Test, now entering commercialization, represents a first example of this next generation tests.

  • Infectious Disease Diagnostic

    Infectious diseases are caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi. Accurate detection of these microorganisms is the first crucial step in diagnosing and efficiently treating the disease, and in containing it from spreading further. Arbor Vita Corporation is focused on one of the most important and challenging areas in this space – rapid influenza detection tests. Arbor Vita is developing rapid diagnostic tests that are suited to be used at points of contact such airports, borders and other places where other methods are not practical.

  • AVC Research Reagents

    Research Reagents

    Arbor Vita has exquisite expertise in generating recombinant proteins and high affinity monoclonal antibodies against viral and cellular targets, and in the characterization of such reagents for use under a variety of applications and protocols.

Arbor Vita Corporation’s A/H7N9 Influenza Rapid Detection Test Authorized for Emergency Use by FDA

A new strain of the avian influenza virus appeared in China in 2013. This particular `bird flu', influenza A/H7N9 virus (detected in China in 2013), kills one in three people infected. In two successive and increasing waves, this virus has moved across China and crossed the Chinese border into Hong Kong, Taiwan and Malaysia1. According to CDC it is possible that the virus can appear in the US2. This past week, another case of influenza A /H7N9 virus was reported in Hong Kong.

This virus caught the attention of the US government and Swiss government because of its pandemic lethal potential. Rapid, simple, and affordable detection is a critical defense against such a threat. Arbor Vita Corporation (AVC), a privately held company, announced today that the United States Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for their AVC A/H7N9 Influenza Rapid Test for the presumptive detection of the influenza A /H7N9 virus (detected in China in 2013) in patients with signs and symptoms of respiratory infection in conjunction with epidemiological risk factors”.

Read Arbor Vita's press release

Read more information about Arbor Vita's A/H7N9 Influenza Rapid Test